Benzinga•2026-04-22
Leerink Partners Maintains Outperform on Revolution Medicines, Raises Price Target to $171RVMD — Revolution Medicines Inc
NASDAQ · Biotechnology · Biotechnology
$141.50+80.23%Market cap18.69B
- Latest Close
- $141.5
- 30-Day Move
- +80.2%
- Market Cap
- $18.7B
- Shares Outstanding
- 198,170,000
- P/B Ratio
- 9.44
- ROE
- -69.3%
NASDAQ:RVMDBiotechnology / BiotechnologyDelayed public snapshot
Revolution Medicines Inc
A read-only Alphactor snapshot forRevolution Medicines Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-22
Topline snapshot
Latest Close
$141.5
30-Day Move
+80.2%
Market Cap
$18.7B
Shares Outstanding
198,170,000
P/B Ratio
9.44
ROE
-69.3%
Not investment advice. Signals and scores shown here are model outputs derived from historical data, not recommendations. Past performance does not guarantee future results. Do your own research before trading. Full disclaimer
Chart snapshot
$141.50
+80.2%last 90 delayed daily bars
Market cap$18.7B
90D High
$155.70
90D Low
$73.00
Avg Volume
3,351,820
What stands out
Net margin is -2833.9%, useful for comparing RVMD against peers in Biotechnology.
RVMD is up 80.2% over the last 30 trading days shown on this page.
Latest operating income is $-362M, which helps anchor the headline ratios with an actual earnings figure.
Research snapshot
Rule of 40
-3161.4%
Dark Pool Short %
64.1%
Fundamentals snapshot
Latest Close
$141.5
30-Day Move
+80.2%
Market Cap
$18.7B
Shares Outstanding
198,170,000
P/B Ratio
9.44
ROE
-69.3%
ROA
-48.0%
Operating Margin
-3145.0%
Net Margin
-2833.9%
Debt / Equity
0.16
Current Ratio
7.14
Latest Revenue
$0
Financial statement snapshot
Revenue
$0
Gross Profit
--
Operating Income
$-362M
Net Income
$-365M
Gross Margin
--
Net Margin
-283388.0%
Current Ratio
7.14
Debt / Equity
0.16
Quality snapshot
Altman Z
13.05
Safe
Piotroski
1
Weak (0-3)
Cash Conversion
0.79x
Rule of 40
-3161.4%
Concerning
Annual financial history
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $35M | $-258M | $-249M | $-235M |
| 2023-12-31 | $12M | $-487M | $-436M | $-358M |
| 2024-12-31 | $0 | $-690M | $-600M | $-568M |
| 2025-12-31 | $0 | $-1.2B | $-1.1B | $-914M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
News snapshot
Benzinga•2026-04-22
HC Wainwright & Co. Reiterates Buy on Revolution Medicines, Maintains $169 Price TargetBenzinga•2026-04-21
Revolution Medicines To Reveal Updated Phase 1/2 Clinical Data For Daraxonrasib In First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts At The 2026 AACR Annual MeetingBenzinga•2026-04-21
Revolution Medicines To Reveal Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor At The 2026 AACR Annual MeetingFinnhub•2026-04-21
Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual MeetingAfter signup
The full sentiment workspace adds context
Go past the public headlines into fuller article history, source cross-checks, and deeper narrative tracking.
Tie news into alerts, watchlists, and conviction changes instead of browsing one static batch of stories.
Insider activity snapshot
Buy Value
$0
Sell Value
$52M
Buys
0
Sells
47
Buy Value
$0
Sell Value
$52M
Buy/Sell Ratio
0.00x
After signup
The full app goes deeper on insider behavior
Inspect longer insider history, recurring buyers and sellers, and the broader transaction context beyond this snapshot.
Continue into deeper institutional and alternative-data views once you sign up.
Recent insider transactions
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-15 | GOLDSMITH MARK A | M | 96,756 | $0.00 |
| 2026-04-15 | GOLDSMITH MARK A | M | 23,244 | $0.00 |
| 2026-04-15 | GOLDSMITH MARK A | Sell | 120,000 | $150.09 |
| 2026-04-15 | GOLDSMITH MARK A | M | 96,756 | $4.73 |
| 2026-04-15 | GOLDSMITH MARK A | M | 23,244 | $4.09 |
| 2026-03-25 | Mancini Anthony | M | 37,450 | $0.00 |
| 2026-03-25 | Mancini Anthony | Sell | 400 | $97.21 |
| 2026-03-25 | Mancini Anthony | Sell | 11,036 | $96.43 |
ETF holders snapshot
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 5,812,166 | 0.03% | 2025-12-31 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 4,167,727 | 0.02% | 2025-12-31 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 2,511,042 | 0.01% | 2026-02-28 |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 2,383,815 | 0.01% | 2026-01-31 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 2,350,316 | 0.01% | 2025-12-31 |
| JANUS INVESTMENT FUND-Janus Henderson Enterprise Fund | 2,086,737 | 0.01% | 2025-12-31 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1,957,684 | 0.01% | 2025-12-31 |
| T. Rowe Price Health Sciences Fund, Inc. | 1,431,908 | 0.01% | 2025-12-31 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Institutional holders snapshot
Qube Research & Technologies
Filed 2025-11-14
--
--
Vanguard Group
Filed 2026-01-29
$1.3B
+6.7%
Farallon Capital
Filed 2026-02-17
$1.2B
-0.3%
FMR LLC (Fidelity)
Filed 2026-02-17
$684M
-8.7%
BlackRock
Filed 2024-08-13
$520M
--
Geode Capital Management
Filed 2026-02-09
$252M
+0.5%
Goldman Sachs
Filed 2026-02-10
$202M
+224.8%
Dark-pool activity snapshot
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.